Livmoniplimab ( None identified - this appears to be a non-existent drug name. )

Immunotherapy

Not submitted to EMA

Not available 1 Clinical Trials

Description

Livmoniplimab is a non-existent drug name; there are no clinical indications or efficacy data available for colorectal cancer (CRC).

Mechanism of Action

Livmoniplimab is not an existing drug, and therefore no mechanism of action can be provided.

Side Effects

No side effects can be listed as this drug does not exist.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03821935 Phase 1

Active, not recruiting

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Japan

Quick Info

Brand Name	None identified - this appears to be a non-existent drug name.
Category	Immunotherapy
EMA Status	Not submitted to EMA
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.

Livmoniplimab (** None identified - this appears to be a non-existent drug name. **)